Език: EN EN
← Назад към резултатите
Набира участници Фаза 2/3 NCT05485961

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis

Фаза 2/3 – комбинирано изпитване
Заболявания: Atherosclerotic Cardiovascular Disease End Stage Kidney Disease Atherosclerotic Cardiovascular Disease in Patients With ESKD

Спонсор: CSL Behring

Налично на: БГ
Обобщение
This is a 2-part (phase 2b/3) prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study. Part 1 (phase 2b) is a dose-finding study for CSL300 vs placebo. Part 2 (phase 3) aims to assess the efficacy of CSL300 on cardiovascular (CV) outcomes and safety in subjects with systemic inflammation and either atherosclerotic cardiovascular disease (ASCVD) or diabetes with end stage kidney disease (ESKD) undergoing maintenance dialysis.
Кой може да участва
Inclusion Criteria: * \- Male or female at least 18 years of age * \- A diagnosis of ESKD undergoing maintenance dialysis for at least 12 weeks * \- Serum hs-CRP ≥ 2.0 mg/L * \- A diagnosis of diabetes mellitus OR ASCVD Exclusion Criteria: * \- Subjects who participated in Part 1 (phase 2b) are not eligible to participate in Part 2 (phase 3) * \- Concomitant use of systemic immunosuppressant drugs * \- Abnormal LFTs * \- Any life-threatening disease expected to result in death within 12 months * \- A history of GI perforation, inflammatory bowel disease (except fully excised ulcerative colitis), or peptic ulcer disease * -Clinically significant active infection or history of opportunistic or invasive fungal infection
Места на провеждане 30
Argentina (1)
FME Lomas de Zamora
Banfield
Австралия (1)
Royal North Shore Hospital (RNSH)
Saint Leonards , New South Wales
Белгия (1)
Onze-Lieve-Vrouwziekenhuis VZW
Aalst
Бразилия (1)
Santa Casa de Misericordia de Belo Horizonte
Belo Horizonte
България (1)
Multiprofile Hospital for Active Treatment - Dobrich AD
Dobrich
Канада (1)
University of Alberta Hospital
Edmonton , Alberta
Китай (1)
Inner Mongolia Baotou City Central Hospital (Baotou Central Hospital)
Baotou Shi
Чехия (1)
Interni Oddeleni Nemocnice
Český Krumlov
Дания (1)
Aalborg Universitetshospital
Aalborg
Франция (1)
CHU Amiens - Nephrology Dialysi Transplantation Department
Amiens
Гърция (1)
University Hospital of Alexandroupolis
Alexandroupoli
Hong Kong (1)
Princess Margaret Hospital
Ho Man Tin
Унгария (1)
Somogy Megyei Kaposi Mor Oktato Korhaz
Kaposvár
Израел (1)
Emek Medical Center
Afula
Италия (1)
Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola-Malpighi
Bologna
Япония (1)
Daiyukai Daiichi Hospital
Ichinomiya-shi , Aichi-ken
Malaysia (1)
Hospital Raja Permaisuri Bainun, Ipoh
Ipoh
Норвегия (1)
Vestre Viken HF - Drammen Sykehus (Sykehuset Buskerud)
Drammen
Полша (1)
Davita Stacja Dializ w Brodnicy
Brodnica
Puerto Rico (1)
Legacy Senior Living
Humacao
Румъния (1)
Centrul de Dializa Fresenius NephroCare Brasov
Brasov
Словакия (1)
Nefrologicka ambulancia Levice - FMC dialyzacne sluzby, s.r.o.
Levice
Южна Корея (1)
SMG - SNU Boramae Medical Center
Ilsan-gu , Seoul
Испания (1)
Centro de dialisis Alcobendas
Alcobendas
Швеция (1)
Karolinska Huddinge
Huddinge
Taiwan (1)
Far Eastern Memorial Hospital
New Taipei City
Тайланд (1)
Maharat Nakhon Ratchasima Hospital
Amphoe Mueang
Турция (1)
Hacettepe University,Faculty of Medicine
Ankara
Великобритания (1)
University Hospitals Birmingham NHS Foundation Trust - Birmingham Heartlands Hospital (BHH)
Birmingham
САЩ (1)
Nephrology of North Alabama
Decatur , Alabama
Технически детайли
Статус
Набира участници
Фаза
Фаза 2/3
Вид изследване
INTERVENTIONAL
Пол
Мъже и жени
Минимална възраст
18 Years
Здрави доброволци
Не
Начална дата
21.10.2022
Крайна дата
27.09.2029
Регистрационен номер
NCT05485961
Източник
anzctr
Запитване за медицински туризъм

Информацията е извлечена автоматично от ClinicalTrials.gov. Консултирайте се с вашия лекар преди да предприемете действия.